What will GW Pharmaceuticals' stock price reach in the next year?
Their forecasts range from $147.00 to $220.00. On average, they anticipate GW Pharmaceuticals' stock price to reach $201.75 in the next year. This suggests that the stock has a possible downside of 7.9%.
What's GW Pharmaceuticals CEO approval rating on Glassdoor?
14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees. Who are some of GW Pharmaceuticals' key competitors?
How did GW Pharmaceuticals'Epidiolex make money last year?
It was approved by the Food and Drug Administration in 2018 to treat seizures resulting from early-onset epilepsy. Last year, Epidiolex brought in $510.5 million in sales, up 70% over 2019, making up nearly all of GW's $527.2 million in revenue for the year.
What does a hold rating mean for GW Pharmaceuticals (gwph)?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares. View analyst ratings for GW Pharmaceuticals or view top-rated stocks. What stocks does MarketBeat like better than GW Pharmaceuticals?
See more
What is happening with GW Pharmaceuticals?
DUBLIN , May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Should I sell GW Pharmaceuticals stock?
GW Pharmaceuticals PLC(GWPH-Q) Rating A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Who bought GWPH stock?
Jazz PharmaceuticalsOn Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ -1.02%), both companies announced in a joint press release.
Who is buying GW Pharmaceuticals?
Jazz Pharmaceuticals PlcShare this article. Jazz Pharmaceuticals Plc has agreed to acquire GW Pharmaceuticals Plc, maker of the first drug derived from the cannabis plant to win approval in the U.S., for $7.2 billion in cash and stock. The price amounts to a premium of about 50% over Cambridge, England-based GW's closing price on Tuesday.
Does GW Pharmaceuticals still exist?
In May 2013, the company became dual-listed on the NASDAQ and AIM. In 2014, the company made a deal with New York to develop clinical trials using cannabidiol (CBD) to treat children who suffer from seizures and other medical complications. In May 2021, Jazz Pharmaceuticals acquired the company.
Is Jazz Pharmaceuticals an acquisition target?
Corinne Cardina: Another deal that was more recently announced just this week, Jazz Pharmaceuticals announced that they were going to be acquiring GW Pharmaceuticals. That is the British company that has the only FDA-approved CBD derived drug, Epidiolex. Jazz may be a new name for pot investors.
Did GW Pharmaceuticals stock split?
GWPH Stock Flies On Takeover Deal Under the terms of the deal, Jazz will pay $220 per American depositary share. That's split in $200 per ADS in cash and $20 in Jazz ordinary shares. The entire deal values GWPH stock at $7.2 billion, or $6.7 billion net of GW Pharma's cash.
How much did Jazz Pharmaceuticals pay for GW Pharmaceuticals?
$7.6 billionThe two companies announced Wednesday that Jazz's acquisition of GW has been completed. This brings the $7.6 billion cash-and-stock deal, first announced in early February, to a close.
How much did GW Pharmaceuticals sell for?
$7.2 billionJazz Pharmaceuticals paying $7.2 billion for cannabis drug maker GW Pharma has investors looking at early-stage psychedelic companies. Tryp Therapeutics is one of only a handful of companies moving into Phase 2 clinical trials with a psychedelic compound.
What company owns Epidiolex?
GW Pharmaceuticals' (GWPH) cannabidiol (CBD) drug Epidiolex has been granted Food and Drug Administration approval for a new indication. Additionally, its previous approval has been expanded to cover a wider age range of patients.
Is Jazz Pharmaceuticals stock a buy?
Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Is GW Pharmaceuticals public?
GW Leads the Pack Another top performing publicly traded cannabis company was GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $225 per share earlier this year.
How were GW Pharmaceuticals' earnings last quarter?
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0....
Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the following people: Mr. Justin D. Gover , CEO & Exec. Director (Age 50, Pay $1.19M) ( LinkedIn Pr...
What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?
14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com . Justin Gover has an approval rating of 80% among GW Pharmaceuticals...
Who are some of GW Pharmaceuticals' key competitors?
Some companies that are related to GW Pharmaceuticals include Royalty Pharma (RPRX) , MERCK Kommanditgesellschaft auf Aktien (MKGAF) , Takeda Ph...
What other stocks do shareholders of GW Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC) , NVIDIA...
What is GW Pharmaceuticals' stock symbol?
GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."
What is GW Pharmaceuticals' stock price today?
One share of GWPH stock can currently be purchased for approximately $218.96.
How much money does GW Pharmaceuticals make?
GW Pharmaceuticals (NASDAQ:GWPH) has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceut...
How many employees does GW Pharmaceuticals have?
GW Pharmaceuticals employs 1,161 workers across the globe.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas.
GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.27.
How much does GW Pharm trade?
GW Pharm now trades around $214 per share, very close to the acquisition price. Therefore, unless you are a professional merger arbitrageur -- one who bets on announced mergers being consummated -- the ship has likely sailed on GW.
How much did Jazz Pharmaceuticals buy GW?
The bulk of the move came on Feb. 3 when Jazz Pharmaceuticals ( NASDAQ:JAZZ) announced it would be purchasing GW for $7.2 billion, or the equivalent of $220 per share, made up of $200 per share in cash and $20 in Jazz stock.
When will Jazz generics be available?
It made up 74% of sales last year, but generics will be coming in 2023. That will likely stifle Jazz's growth, unless some of its other drugs in oncology, specifically lung cancer, catch on. But those bring in relatively small dollar amounts today.
Here's why this shares of this cannabinoid drug company will keep soaring within the next year
Zhiyuan Sun is a statistician with a knack for analyzing clinical trials and company financials. Investing in healthcare and cannabis is his passion, as well as looking out for new, actionable stock investment ideas in these sectors. Lately expanding into innovations in cryptocurrency alongside biotech/cannabis content. Fool since April 2020.
Track record of growth
In the first quarter of 2020, sales of Epidiolex in U.S. more than tripled to $106.1 million over the same period last year. Furthermore, sales growth was the strongest during March, amid the COVID-19 pandemic. The company's latest wave of healthcare providers consists of 1,000 new prescribers recommending the drug to patients.
New expansion opportunities
This year, GW Pharmaceuticals is working to bring Epidiolex to Italy and Sweden. In France, a program offering early access to the drug has been very successful, and patient count continues to grow.
Takeaways for investors
Although GW Pharmaceuticals still has a way to go before breaking even, it has over $500 million in cash on its balance sheet to offset such losses. The company also has no long-term debt.
